A Virologist’s Tumor Shrunk After Virus Injections—but It Was No Cure Trial

In 2020, Croatian virologist Beata Halassy injected a recurrent breast tumor with two laboratory-grown viruses. The mass shrank before surgery, and the latest published follow-up recorded 45 months without recurrence—but this was one uncontrolled case, not evidence of a cure.

That distinction remains essential. The treatment combined experimental injections, surgical removal and a subsequent year of targeted therapy, while virus-based treatments for breast cancer remain investigational rather than an approved alternative to standard care.

What happened in the 2020 self-experiment

Halassy’s breast cancer was first diagnosed in 2016 and treated with mastectomy and chemotherapy. A local recurrence was removed in 2018, but by 2020 a monitored abnormality at the surgical site had developed into a solid tumor involving the skin and pectoral muscle. Imaging found no distant metastases or regional lymph-node spread.

Because Halassy was an experienced virologist, she could cultivate and characterize viruses in a laboratory. Her oncologists monitored the tumor and were prepared to stop the experiment if it progressed or produced unacceptable effects. The preparations were nevertheless research grade, not clinical grade, and had not undergone the manufacturing and safety controls expected of an approved medicine.

The peer-reviewed 2024 case report describes seven intratumoral applications of the Edmonston-Zagreb measles vaccine strain, followed by three applications of vesicular stomatitis virus over roughly two months. Four imaging assessments placed the initial tumor volume at 2.47 cubic centimeters; the excised tumor measured 0.91 cubic centimeters.

The physical changes were also clinically relevant. A hard, fixed and inflamed mass became smaller, softer and mobile, while the tissue removed at surgery no longer invaded the overlying skin or underlying muscle. Examination of the excised tumor found extensive immune-cell infiltration, including increased B cells, cytotoxic T cells and macrophages.

The result cannot be assigned to the viruses alone

The chronology supports the conclusion that shrinkage occurred during the injection period, but it cannot establish how much of the response each virus caused. There was no control patient, randomization or comparison arm, and only one person received the protocol. Even the two viral phases cannot be separated reliably because they were administered sequentially to the same tumor.

The injections were also only one part of Halassy’s cancer treatment. Surgeons removed the residual tumor after the experimental phase. Pathology showed that the recurrence was HER2-positive, and she then completed one year of trastuzumab, an established targeted treatment for appropriate HER2-positive cancers.

For that reason, “cured her own cancer with viruses” overstates the evidence. The defensible finding is narrower: a closely monitored tumor shrank after experimental intratumoral virotherapy, became easier to remove, and was followed by surgery, adjuvant treatment and a documented remission lasting 45 months. The published record does not justify automatically extending that follow-up to six years.

Why viruses can attack tumors

Oncolytic virotherapy uses viruses that can infect and damage cancer cells, potentially releasing tumor material that alerts the immune system. Some candidates are modified to favor malignant tissue or to stimulate immunity; others exploit biological features that make certain tumor cells susceptible to infection.

Halassy’s team selected a vaccine-lineage measles virus and a laboratory-adapted vesicular stomatitis virus. The paper’s authors reasoned that using one virus and then another might reduce the chance that newly formed neutralizing antibodies would blunt the later phase. That remains a hypothesis arising from the protocol, not a clinically validated recipe.

The reported short-term tolerance also should not be generalized. Halassy experienced painful early injections and, after the first vesicular stomatitis virus dose, fever and chills that resolved within three days. The absence of a serious adverse event in one highly supervised patient cannot determine the frequency or severity of risks in a broader population.

Where breast-cancer virotherapy stands now

Formal research has continued, but its status underscores the distance between a striking case and routine treatment. A US phase I study of an engineered measles-virus derivative in metastatic breast cancer was designed primarily to determine safety and dosing, with antitumor activity assessed only preliminarily; the ClinicalTrials.gov record says the study closed to accrual on June 9, 2025.

US regulatory approval does exist for an oncolytic virus, but not for breast cancer. The FDA indication for Imlygic, or talimogene laherparepvec, covers local treatment of certain unresectable lesions in melanoma that has recurred after surgery. It does not authorize Halassy’s measles-and-vesicular-stomatitis-virus regimen or establish it as a breast-cancer therapy.

These boundaries matter because laboratory viral preparations can contain residual material from the cells used to grow them, and viral behavior depends on strain, dose, route, tumor biology and the patient’s immune status. Reproducing the headline action without Halassy’s expertise, containment facilities, imaging and oncology supervision would not reproduce the conditions of the case—and could cause infection, contamination, delayed standard treatment or other serious harm.

What the case actually contributes

The scientifically useful signal is not that patients can manufacture a cancer treatment. It is that intensive, locally delivered virotherapy before surgery may deserve controlled study in selected tumors, including earlier-stage disease where the immune system and general health may be less compromised than in heavily pretreated metastatic cancer.

A proper trial would need standardized clinical-grade material, predefined dosing, safety surveillance and enough participants to distinguish treatment effects from individual variation. It would also have to separate the contribution of virotherapy from surgery and systemic drugs, while measuring recurrence and survival over a defined follow-up period.

Halassy’s experience therefore sits between observation and evidence. It produced measurable tumor changes and a valuable research question, but neither one patient’s remission nor a dramatic biological response establishes a safe, effective breast-cancer treatment. Its strongest present-day consequence is a case for rigorous trials—not a protocol for self-treatment.

Also read:

• Billie Eilish has revealed she's enjoyed "a lot of good sex" this year, just months after expressing a desire for her dating life to remain private "ever again."
• A Dubai princess, known for announcing her divorce via an Instagram post, was seen on a date with a well-known rapper
• Adult Star's Career Revealed After Uncle Comments on Her Debut Video